Sarepta Therapeutics remains focused on developing first-in-class RNA-based therapies to improve and save the lives of people affected by rare and infectious diseases. Our commitment is to translate our unique RNA-based technology into therapeutics for serious and life-threatening genetic-based diseases.
Our diverse pipeline of RNA-based therapies have yielded our lead program, eteplirsen, for Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases. We hav... More >>
Recent Press Releases
|11/19/13||Sarepta Therapeutics to Present Company Overview at Upcoming Conferences|
|Webcast Accessible via Sarepta Therapeutics Website
CAMBRIDGE, MA -- (Marketwired) -- 11/19/13 --
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in December. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.
Deutsche Bank BioFEST in Boston, MA on Monday, December 2, 2013 at 5:10 p.m. Eastern Time.
|11/12/13||Sarepta Therapeutics Announces Third Quarter 2013 Financial Results and Recent Corporate Developments|
|Ongoing Discussions With FDA Remain a Priority to Advance Eteplirsen Program in Duchenne Muscular Dystrophy; Updated Guidance Lowers Full-Year Operating Loss to $80-90 Million Range; Strong Financial Position With Approximately $281 Million in Cash and Other Investments at Quarter End
CAMBRIDGE, MA -- (Marketwired) -- 11/12/13 --
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and nine months ended Sept... |
|11/12/13||Sarepta Therapeutics Announces FDA Considers NDA Filing for Eteplirsen Premature in Light of Recent Competitive Drug Failure and Recent DMD Natural History Data|
|FDA Questions Dystrophin as a Biomarker Due to Failed Studies of Other Investigational Drugs for DMD; FDA Questions 6-Minute Walk Test Results for Eteplirsen, Suggesting Study Population Should Be Stable Over Two-Year Timeframe Due to Recent Natural History Data; FDA Requests Further Discussion on Endpoints, Design of Confirmatory Clinical Study
CAMBRIDGE, MA -- (Marketwired) -- 11/12/13 -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT) today provided an update on its discussions with the U.S. Food ... |
|10/24/13||Sarepta Therapeutics to Announce Third Quarter 2013 Financial Results and Corporate Update on November 12, 2013|
|CAMBRIDGE, MA -- (Marketwired) -- 10/24/13 --
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will report third quarter financial results before the NASDAQ Global Market opens on Tuesday, November 12, 2013. Subsequently, at 8:00 a.m., Eastern Time (5:00 a.m., Pacific Time), Chris Garabedian, Sarepta's president and chief executive officer, and Sandy Mahatme, Sarepta's chief financial officer, will host a conference call to discuss third quarter fina... |
In the News
|There are currently no events scheduled.|